fashion -WSS

fashion

author：comprehensive 2025-10-02 22:26:27 - browse：16

Stock exchange — Drew Angerer/Getty Images

Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two small studies, leading shares to surge in pre-market trading.

In a 12-week Phase 2a study, the daily pill in a capsule formulation led to 6.2% placebo-adjusted weight loss. In a separate 12-week pharmacokinetics study, the company tested a new tablet formulation of the drug, called GSBR-1290, and it led to placebo-adjusted weight loss of up to 6.9%.

Though it’s difficult to compare across different studies, the results appear to approach the levels of weight loss seen at 12 weeks in a separate Phase 2 study of Eli Lilly’s GLP-1 pill called orforglipron. That entire study lasted 36 weeks, but at 12 weeks, participants had about 6%-7% placebo-adjusted weight loss.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Why did Pfizer dish out millions for a Super Bowl ad?

WSS

These geoengineering technologies could help combat the climate crisis, scientists say

Private equity deals in Medicare Advantage declines

Key House Republican on health care plans exit from Congress

Biogen Alzheimer’s drug launch off to slow start

Make 'food is medicine' a key part of White House nutrition meeting

Listen: PBM conflicts, RSV vaccines, & the future of flu season

leisure time

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Activists slam private health insurers over coverage restrictions

Senators start work on Medicare physician payment reform

Tori Bowie and the unacceptable rates of Black maternal death

Bacterial infection may be ‘key event’ in endometriosis, study says

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Continuity nursing helped my family in our darkest PICU moments

PhRMA sues HHS over Medicare drug price negotiation

Apple is now the first public company to be valued at $3 trillion

Medicare threatens to cut off funding for HCA's Mission hospital

entertainment

Industry veterans launch new biotech VC with $310M

Did the public have the right to know Arthur Ashe had AIDS?

Readout LOUD podcast: How biotech is using artificial intelligence

Connecting traumatic brain injury and domestic violence

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

What we’ve learned from the Aduhelm mess

explore

explore

entertainment

leisure time